Abstract:Proper evaluation of therapeutic responses in Chagas disease is hampered by the prolonged persistence of antibodies to Trypanosoma cruzi measured by conventional serological tests and by the lack of sensitivity of parasitological tests. Previous studies indicated that tGPI-mucins, an α-Gal (α- d -Gal p (1→3)-β- d -Gal p (1→4)- d -GlcNAc)-rich fraction obtained from T . cruzi trypomastigotes surface coat, elicit a strong and protective antibody response in infected individuals, which disappears soon after successful treatment. The cost and technical difficulties associated with tGPI-mucins preparation, however, preclude its routine implementation in clinical settings. We herein developed a neoglycoprotein consisting of a BSA scaffold decorated with several units of a synthetic α-Gal antigenic surrogate (α- d -Gal p (1→3)-β- d -Gal p (1→4)-β- d -Glc p ). Serological responses to this reagent, termed NGP-Tri, were monitored by means of an in-house enzyme-linked immunosorbent assay (α-Gal-ELISA) in a cohort of 82 T . cruzi -infected and Benznidazole- or Nifurtimox-treated children (3 days to 16 years-old). This cohort was split into 3 groups based on the age of patients at the time of treatment initiation: Group 1 comprised 24 babies (3 days to 5 months-old; median = 26 days-old), Group 2 comprised 31 children (7 months to 3 years-old; median = 1.0-year-old) and Group 3 comprised 26 patients (3 to 16 years-old; median = 8.4 years-old). A second, control cohort (Group 4) included 39 non-infected infants (3 days to 5 months-old; median = 31 days-old) born to T . cruzi -infected mothers. Despite its suboptimal seroprevalence (58.4%), α-Gal-ELISA yielded shorter median time values of negativization (23 months [IC 95% 7 to 36 months] vs 60 months [IC 95% 15 to 83 months]; p = 0.0016) and higher rate of patient negative seroconversion (89.2% vs 43.2%, p < 0.005) as compared to conventional serological methods. The same effect was verified for every Group, when analyzed separately. Most remarkably, 14 out of 24 (58.3%) patients from Group 3 achieved negative seroconversion for α-Gal-ELISA while none of them were able to negativize for conventional serology. Detailed analysis of patients showing unconventional serological responses suggested that, in addition to providing a novel tool to shorten follow-up periods after chemotherapy, the α-Gal-ELISA may assist in other diagnostic needs in pediatric Chagas disease. The tools evaluated here provide the cornerstone for the development of an efficacious, reliable, and straightforward post-therapeutic marker for pediatric Chagas disease. The limits of the current criterion for cure, i.e., negative seroconversion determined by conventional serology, and the lack of validated and sensitive markers for early assessment of response to trypanocidal drugs in Chagas disease stress the necessity of novel therapeutic response markers. Towards this goal, we herein developed by synthetic chemistry a neoglycoprotein bearing an α-Gal antigenic surrogate, termed NGP-Tri, and evaluated its performance in a large cohort of T . cruzi -infected and treated children. An α-Gal-ELISA built upon NGP-Tri showed a very good performance on the assessment of therapy efficacy, as it displayed significantly shorter median time value of negativization and higher rate of patient negative seroconversion as compared to conventional serology methods. These findings indicate that the tools developed here, as well as optimized versions derived from them, should have a positive impact on the clinical management of Chagas disease and the identification and/or clinical validation of novel drug candidates for the treatment of T . cruzi infections.

Antibody epitope repertoire analysis enables rapid antigen discovery and multiplex serology

Identification of highly conserved Trypanosoma cruzi antigens for the development of a universal serological diagnostic assay

Chagas Disease Diagnosis with Trypanosoma cruzi-Exclusive Epitopes in GFP

A Multi-Epitope Protein for High-Performance Serodiagnosis of Chronic Chagas Disease in ELISA and Lateral Flow Platforms

Diversity of Chagas disease diagnostic antigens: Successes and limitations

Accuracy of chimeric proteins in the serological diagnosis of chronic chagas disease – a Phase II study

Recombinant proteins as promising antigens applied to the immunodiagnosis of Chagas disease: a scoping review

Serological confirmation of Chagas' disease by a recombinant and peptide antigen line immunoassay: INNO-LIA chagas

The use of peptides for immunodiagnosis of human Chagas disease

Evaluation of the Epitogen Lyme Detect IgG ELISA: a novel peptide multiplexing approach

Aptamer Based, Non-PCR, Non-Serological Detection of Chagas Disease Biomarkers in Trypanosoma cruzi Infected Mice

Advancing Toxoplasma gondii multiplex serology

Chagas Disease Serological Test Performance in U.S. Blood Donor Specimens

Evaluation of chimeric recombinant antigens for the serodiagnosis of Trypanosoma cruzi in dogs: a promising tool for Chagas disease surveillance

Mapping the antigenicity of the parasites in Leishmania donovani infection by proteome serology

Identification of reactive Borrelia burgdorferi peptides associated with Lyme disease

APRANK: Computational Prioritization of Antigenic Proteins and Peptides From Complete Pathogen Proteomes

Discovery of Two Novel Immunoepitopes and Development of Peptide-based Sarcoidosis Immunoassay

An α-Gal antigenic surrogate as a biomarker of treatment evaluation in Trypanosoma cruzi -infected children. A retrospective cohort study

A Peptide Microarray Platform Approach for Discovery of Immunodominant Antibody Epitopes

Challenges in Chlamydial Serology: Insights from a Belgian and a Dutch Population Cohort